Publicar

EFICÁCIA, SEGURANÇA E PERSPECTIVAS DO CLESROVIMABE (MK-1654) NA PROFILAXIA DO VÍRUS SINCICIAL RESPIRATÓRIO (VSR) EM LACTENTES: UMA REVISÃO SISTEMÁTICA

Doi: 10.47094/CESMED.2025/32

PALAVRAS CHAVE: Anticorpos Monoclonais. Lactentes. Vírus Sincicial Respiratório Humano.

KEYWORDS: Monoclonal Antibodies. Infants. Human Respiratory Syncytial Virus.

ABSTRACT:
INTRODUCTION: Clesrovimab (MK-1654) is a monoclonal antibody being studied for prophylaxis in infants against Human Respiratory Syncytial Virus (RSV), the leading cause of acute lower respiratory tract infections in infants [1,2]. In the Midwest, this virus circulates seasonally, predominating from March to July [3]. In 2018, MK-1654 received Fast Track designation from the U.S. Food and Drug Administration (FDA) and is currently undergoing review, with approval anticipated for 2025. Due to its extended half-life, clesrovimab allows a single dose to cover a full RSV season. [4]. OBJECTIVE: To observe the efficacy and safety of clesrovimab in the prophylaxis of serious infections and hospitalizations associated with RSV in infants.

Autores

  • Ana Júlia Eugênia Alnert Dias

  • Lorenna Rocha Lobo e Silva Mamede

  • Matheus Feliph Alves Arantes

  • Náscar Katerine do Carmo

Download